DDInter1084 DDInter1676
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lomefloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Lomefloxacin {u} (Compound) binds {v} (Gene) TOP2A
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Potassium low
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Daunorubicin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Lomefloxacin (Compound) resembles Moxifloxacin (Compound)
Lomefloxacin (Compound) binds TOP2A (Gene)
Lomefloxacin (Compound) causes Potassium low (Side Effect)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Lomefloxacin may lead to a major life threatening interaction when taken with Methylprednisolone
Lomefloxacin may lead to a major life threatening interaction when taken with Ivosidenib